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Introduction
Inosine 5′-monophosphate dehydrogenase (IMPDH) is
a rate-limiting enzyme in the de novo pathway for syn-
thesis of guanine nucleotides, which are essential for
normal cell proliferation and function. IMPDH cat-
alyzes the NAD-dependent conversion of inosine
monophosphate to xanthine monophosphate, which
is subsequently converted to guanosine monophos-
phate (GMP) by GMP synthase. The only alternative
pathway for guanine nucleotide biosynthesis is
through the salvage of guanine to GMP by hypoxan-
thine-guanine phosphoribosyltransferase (HPRT), an
enzyme encoded by a gene on the X chromosome (Fig-
ure 1). The relative contributions of the de novo and
salvage pathways to guanine nucleotide biosynthesis in
different tissues and cell types have not been defini-
tively determined, although this issue is clearly central
to our understanding of both the pathophysiology of
inherited disorders of enzymes in these pathways and
the therapeutic effects of selected pharmacological
inhibitors of these enzymes. IMPDH activity in human
tissues is composed of the activities of two separate but
very closely related IMPDH isoenzymes, termed type I
(1) and type II (2), which are 84% identical at the amino
acid level and possess indistinguishable catalytic activ-
ities. However, the regulation of expression of the two
IMPDH genes differs dramatically (3, 4). The increased
IMPDH activity observed in replicating or neoplastic
cells is largely due to increased expression of the type II
IMPDH mRNA, whereas expression of the type I gene
is relatively unaffected by cell proliferation or transfor-
mation (5, 6). The expression of both genes is, howev-
er, significantly increased by mitogen activation of
peripheral blood lymphocytes (7).
A survey of relative IMPDH mRNA levels in human
tissues demonstrated significant variability in the pat-
tern of distribution of the type I transcript, whereas
expression of the type II transcript, while generally
higher than that of type I, was far less variable (8). The
observations that the expression of the IMPDH gene is
tightly linked with both cellular proliferation and
transformation (9, 10) have led to an interest in devel-
oping IMPDH inhibitors that deplete intracellular
guanine nucleotide pools. It has been shown that
administration of IMPDH inhibitors to cultured cells
results in inhibition of DNA synthesis (11) and cell-
cycle arrest at the G1-S boundary (12, 13). Inhibitors of
IMPDH have also been shown to possess antineoplas-
tic (14, 15), antiviral (16), antiparasitic (17), and
immunosuppressive (18, 19) activities, and to induce
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Inosine 5′-monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in the de novo syn-
thesis of guanine nucleotides, which are also synthesized from guanine by a salvage reaction cat-
alyzed by the X chromosome–linked enzyme hypoxanthine-guanine phosphoribosyltransferase
(HPRT). Since inhibitors of IMPDH are in clinical use as immunosuppressive agents, we have
examined the consequences of knocking out the IMPDH type II enzyme by gene targeting in a
mouse model. Loss of both alleles of the gene encoding this enzyme results in very early embryon-
ic lethality despite the presence of IMPDH type I and HPRT activities. Lymphocytes from IMPDH
II+/– heterozygous mice are normal with respect to subpopulation distribution and respond nor-
mally to a variety of mitogenic stimuli. However, mice with an IMPDH II+/–, HPRT–/o genotype
demonstrate significantly decreased lymphocyte responsiveness to stimulation with anti-CD3 and
anti-CD28 antibodies and show a 30% mean reduction in GTP levels in lymphocytes activated by
these antibodies. Furthermore, the cytolytic activity of their T cells against allogeneic target cells
is significantly impaired. These results demonstrate that a moderate decrease in the ability of
murine lymphocytes to synthesize guanine nucleotides during stimulation results in significant
impairment in T-cell activation and function.
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the differentiation of a variety of human tumor cell
lines, including leukemic (20), breast cancer (21), and
melanoma (22) cells.
In order to understand better the homeostatic mech-
anisms responsible for regulating intracellular guanine
nucleotide synthesis through the de novo as opposed
to the salvage pathway and to determine the relative
biological roles of IMPDH type I and type II enzymes
in the development and function of lymphocytes, we
developed a specific gene-targeting construct to inacti-
vate the murine IMPDH type II gene. Homozygous loss
of the IMPDH type II gene results in early embryonic
lethality. Although IMPDH II heterozygous or HPRT-
deficient mice do not show any abnormal phenotype,
T lymphocytes from mice with combined deficiencies
of HPRT and IMPDH activities demonstrate both
impaired proliferative responses to mitogen and
decreased cytolytic function.
Methods
Construction of the IMPDH II targeting vector and embryon-
ic stem cell selection. The pJNS2 vector (provided by Bev-
erly Koller, Department of Medicine, University of
North Carolina), containing Neo and HSV-TK genes
under the regulation of the phosphoglycerate kinase
(PGK) promoter, was used for making the knock-out
construct. IMPDH type II gene fragments of 2.4 kb con-
taining exons 1 through 5 and 4.6 kb containing exons
10 through 14 were inserted into NotI, XhoI, and XbaI
sites 5′ and 3′ to the Neo gene, respectively (Figure 2).
Mouse 129 strain embryonic stem (ES) cells were trans-
fected using electroporation and selected in the pres-
ence of 200 µg/mL G418 and 0.5 µg/mL ganciclovir.
Genomic DNA from selected ES clones was digested
with BglII, separated on 0.8% agarose gels, transferred
onto Zeta-Probe nylon membranes (Bio-Rad Labora-
tories Inc., Hercules, California, USA), and hybridized
with an [α-32P]-dCTP-labeled 0.6-kb DNA probe (3000
Ci/mmol; Amersham Pharmacia Biotech, Piscataway,
New Jersey, USA) located 5′ to the first exon (Figure 2).
Labeling was done using a Random Primer Labeling kit
(Promega Corp., Madison, Wisconsin, USA). Two ES
clones heterozygous for recombination at the IMPDH
II locus were microinjected into C57BL/6 blastocysts to
generate chimeric mice.
Breeding and genotyping of offspring. Male mice with
65–100% chimerism based on coat color were bred with
C57BL/6 females (The Jackson Laboratory, Bar Harbor,
Maine, USA). Genotyping was performed on 2- to 4-
week-old F1 agouti offspring by Southern hybridiza-
tion analysis of tail DNA using High Efficiency
Hybridization System (Molecular Research Center Inc.,
Cincinnati, Ohio, USA).
PCR analysis of blastocysts. To obtain blastocysts, female
mice were superovulated by injecting 5 U of pregnant
mares’ serum (Sigma Chemical Co., St. Louis, Missouri,
USA) intraperitoneally followed 48 hours later by 5 U
of human chorionic gonadotropin (Sigma Chemical
Co.). Blastocysts were collected from 3.5-days-post-
coitum (dpc) uteri, washed in M2 medium (Cell & Mol-
ecular Technologies Inc., Phillipsburg, New Jersey,
USA) and PBS, and digested in 20 µL of PCR lysis
buffer (50 mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl
[pH 8.3], 0.01% gelatin, 0.45% NP-40, 0.45% Tween-20,
and 100 µg/mL proteinase K) at 55°C overnight. One
µL of sample was used in each PCR reaction containing
250 µM of the four deoxyribonucleoside triphosphates,
100 ng of each primer, and 0.5 units of Taq polymerase
(Roche Molecular Biochemicals, Indianapolis, Indiana,
USA). Two sets of oligonucleotide primers were used in
separate PCR reactions, since they gave rise to ampli-
fied fragments of similar size. The first set of primers,
specific for the wild-type allele, includes a forward
primer (E5F2) from exon 5 of the type II gene: 5′-GGAA-
GAGCATGACCGGTTCTTGGA-3′ ; and a reverse primer
(E6R1) from exon 6: 5′-AGGGGCGACCACCAAATCTT-3′.
The second set of primers, specific for the recombinant
allele, includes a forward primer (PNT 3F) from the 3′
end of the Neo gene cassette: 5′-GAGATCAGCAGCCTCT-
GTTCCAC-3′ ; and a reverse primer (E10R1) from exon
10: 5′-GAGACCTTGTACACTGCTGTGGCT-3′.
Northern hybridization. Isolation of RNA and North-
ern blots were performed as described previously (4).
IMPDH mRNAs were detected with 1.5-kb mouse
IMPDH type I and type II full-length cDNA probes,
and HPRT mRNA was detected with a 0.5-kb mouse
HPRT cDNA probe extending from exon 3 to exon 9
obtained by RT-PCR.
In vitro lymphocyte activation. Mouse splenocytes were
cultured in RPMI-1640 (Life Technologies Inc.,
Rockville, Maryland, USA) containing 10% heat-inacti-
vated FBS (Sigma Chemical Co.), 55 µM β-mercap-
toethanol, 100 U/mL penicillin, and 100 µg/mL strep-
tomycin. For T-cell stimulation, Con A (Pharmacia
Biotech AB, Uppsala, Sweden) was used at 5 µg/mL;
PMA and ionomycin (Calbiochem-Novabiochem
Corp., San Diego, California, USA) were used at 10
ng/mL and 250 ng/mL, respectively; and 1 µg/mL of
anti-CD3 (500-A2; Caltag Laboratories Inc.,
Burlingame, California, USA) and 2.5 µg/mL of anti-
CD28 (37.51.1; Caltag Laboratories Inc.) in 100 µL vol-
ume were used to coat each of 96 wells at 37°C for 4–6
hours. For B-cell stimulation, LPS (Sigma Chemical
Co.) was used at 20 µg/mL.
Lymphocyte proliferation assays. Splenocytes were plat-
ed in a 96-well plate at a density of 105 cells per well for
T-cell mitogens, and 5 × 104 cells per well for LPS stim-
ulation; 1 µCi of [methyl-3H]-thymidine (80 Ci/mmol;
Amersham Pharmacia Biotech) was added to each well
during the final 6 hours of culture. Cells were harvest-
ed at the indicated time onto glass fiber filters (Packard
Instrument Co., Meriden, Connecticut, USA) and
counted in Microscint 20 scintillation fluid (Packard
Instrument Co.) by a Top Count (Packard Instrument
Co.). For testing drug sensitivity, cells were stimulated
with either Con A or antibodies in the absence or pres-
ence of various concentrations of mycophenolic acid
(MPA) and harvested after 72 hours.
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51Cr-release assay. To set up mixed lymphocyte reaction
(MLR), 5 × 106 cells/mL of irradiated (30 Gy) DBA/2
(H-2d) mouse splenocytes used as stimulators were
mixed with 2 × 106 cells/mL of responder splenocytes
(H-2b) for 5 days. To prepare target cells for 51Cr-release
assays, 107 P815 cells (H-2d; American Type Culture
Collection, Rockville, Maryland, USA) were labeled
with 150 µCi [51Cr]-sodium chromate (250–500
mCi/mg Cr; Amersham Pharmacia Biotech) by incuba-
tion at 37°C for 45 minutes. To test specific killing
activity of cytotoxic T cells generated from MLR, 100
µL of 51Cr-labeled P815 cells (1 × 104) were mixed with
100 µL of effector cells at indicated effector:target (E:T)
ratios and incubated at 37°C for 4 hours. The wells
containing target cells with medium alone were used as
spontaneous release controls, and wells containing tar-
get cells plus 5% Triton X-100 were used as maximum
release controls. Results are expressed as a percentage
of specific lysis as calculated by the following formula:
(release with effector cells – spontaneous release) /
(maximum release – spontaneous release).
Measurement of nucleotides. To extract intracellular
nucleotides, cell pellets were extracted with cold 5% per-
chloric acid and incubated on ice for 10 minutes fol-
lowed by a 10-minute centrifugation. Supernatants
were then adjusted to pH 6–7 using 3M KOH/3M
KHCO3 solution. Nucleotide pools were quantitated by
HPLC, using a Whatman Inc. (Clifton, New Jersey,
USA) Partisil-10 SAX anion exchange column and a lin-
ear gradient of 0.5 M KH2PO4 pH 4.5 versus 7 mM
KH2PO4 pH 3.8 monitored at 254 nm. Total intracel-
lular nucleotide levels were calculated by comparing
with peaks generated by calibrated amounts of pure
ATP and GTP.
Results
Generation of IMPDH type II–deficient mice. To inactivate
the IMPDH type II gene in mouse ES cells, we con-
structed an IMPDH type II gene targeting construct in
which a 1.7-kb genomic XbaI fragment encompassing
exon 6 through exon 9 is replaced with a PGK-Neo cas-
sette (Figure 2a). A targeted recombination event with
this vector would introduce a BglII site at the 3′ end of
the Neo gene, giving rise to a distinct 6-kb BglII frag-
ment in the recombinant as opposed to the 11-kb BglII
genomic fragment as detected by a probe 5′ to exon 1
(Figure 2, a and b). ES cells were electroporated with the
linearized vector and selected in the presence of G418
and ganciclovir. Cells containing the correctly targeted
allele were identified by Southern blot hybridization
and constituted 10–15% of the clones analyzed. Two ES
clones, each containing a single targeted allele, were
microinjected into C57BL/6 (B6) blastocysts to gener-
ate chimeric mice.
Chimeric male mice were then mated with B6 females
with successful germ line transmission. The ES cell line
(E14TG2a) that we used for the initial transfection is a
variant of the E14 line and is deficient in X chromo-
some–linked HPRT activity (23). Since F1 female mice
generated from this line will be HPRT+/–, we back-
crossed the IMPDH II heterozygous F1 male (IMPDH
II+/–, HPRT+/o) with B6 wild-type females to generate off-
spring containing wild-type HPRT. To generate mice
homozygous-deficient in IMPDH II, IMPDH II+/– mice
were interbred. The genotypes of offspring were deter-
mined by Southern blot analysis of tail DNA. Of 159
offspring examined, 57 were wild-type (36%) and 102
were IMPDH II+/– (64%). No homozygous-deficient mice
(IMPDH II–/–) were found, indicating that loss of both
alleles of the IMPDH type II gene results in embryonic
lethality. Since HPRT is an enzyme that uses guanine in
a phosphoribosylation reaction of the salvage pathway
to generate guanine nucleotides (Figure 1), we supple-
mented drinking water with 2 mM guanosine to deter-
mine whether the salvage of guanine through the HPRT
pathway could compensate for the loss of IMPDH type
II activity. No IMPDH II–/– mice were found in 28 pups
analyzed. IMPDH+/– mice were phenotypically and devel-
opmentally normal and were fertile.
To determine the stage of development at which the
homozygous-deficient embryos were lost, blastocysts
were isolated at 3.5 dpc from superovulated IMPDH II+/–
females that had been bred with IMPDH II+/– males. PCR
was performed using two sets of oligonucleotide primers
as described in Methods. Of 122 blastocysts analyzed, 36
contained only wild-type alleles, 78 were heterozygous,
and 8 were homozygous for presence of the recombinant
alleles only (Figure 3). Since the percentage of blastocysts
that are homozygous-deficient (6.5%) is much less than
the expected 25%, this result indicates that the majority
of the IMPDH II–/– mice did not develop to the blastocyst
stage. Embryos from heterozygous matings were also
analyzed at early gestation times using embryos from
wild-type B6 matings as normal controls. At least ten sec-
tions were made for each uterus, and early embryonic
development was determined by the finding of an ecto-
dermal and endodermal egg cylinder within the decidual
swelling by light microscopy (data not shown). The per-
centage of empty decidua was only slightly higher in the
IMPDH II+/– matings compared with that in the B6 mat-
ings at age 7.5 dpc. These results indicate that few, if any,
of the IMPDH II–/– blastocysts implanted to induce a
decidual response, further supporting very early embry-
onic lethality.
In order to determine whether loss of guanine salvage
by HPRT would enhance any phenotypic alterations of
heterozygous IMPDH II–deficient animals, IMPDH II
heterozygous, HPRT wild-type F1 males (IMPDH II+/–,
HPRT+/o) were bred with IMPDH II+/–, HPRT+/– F1
females to generate male offspring with four different
genotypes: (a) wild-type for both IMPDH II and HPRT
(IMPDH II+/+, HPRT+/o); (b) IMPDH II wild-type, HPRT-
deficient (IMPDH II+/+, HPRT–/o); (c) IMPDH II+/–,
HPRT+/o; and (d) IMPDH II+/–, HPRT–/o. Mice containing
each of these genotypes had no evident growth or
behavioral abnormalities and were fertile. Subsequent
studies were conducted on these mice between 5 and 10
weeks of age.
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Effect of loss of IMPDH II or HPRT activity on IMPDH type
I expression. In order to determine whether the IMPDH
type I enzyme was increased in expression in IMPDH
type II+/– and/or HPRT-deficient mice and whether the
expression of the IMPDH and the HPRT were coordi-
nately regulated, we measured the mRNA levels of
IMPDH type I, IMPDH type II, and HPRT in tissues
from mice with the four different genotypes. As expect-
ed, the mRNA levels for IMPDH types I and II, as well
as HPRT, were markedly increased in splenic lympho-
cytes after mitogen stimulation (Figure 4a). The level
of IMPDH type II mRNA in stimulated splenocytes
from the IMPDH II+/– mice was approximately 70% of
the wild-type level as calculated by densitometry after
normalization to the 28S rRNA level. The level of
IMPDH type I mRNA was similar in all groups, and
HPRT deficiency did not result in an upregulation of
IMPDH I or II mRNAs. The relative levels of RNAs
from a number of tissues from wild-type and IMPDH
II+/–, HPRT–/o mice were also compared (Figure 4b).
There was approximately a 30% reduction in type II
mRNA levels in lung, liver, heart, and brain in
IMPDH+/– mice as compared with wild-type after nor-
malization to the 28S rRNA level. Of particular inter-
est is the lack of detectable IMPDH I mRNA in mouse
livers, suggesting that the type II enzyme represents the
major enzyme for de novo synthesis of guanine
nucleotides in this organ. Although expression of type
I mRNA is not altered in most tissues from IMPDH
II+/–, HPRT–/o mice, there is a small increase (30%) in
type I mRNA levels in the brains of these mutant mice
as compared with the wild-type animals.
IMPDH types I and II proteins varied in rough pro-
portion to the levels of these corresponding mRNAs.
There was no alteration in expression of the type I pro-
tein in IMPDH II+/–, HPRT-deficient mice, with the
exception of a slightly increased amount of type I pro-
tein in the brain (data not shown).
IMPDH enzymatic activity is increased more than six-
fold in wild-type splenic lymphocytes upon Con A stim-
ulation. This increment is reduced by approximately 40%
in IMPDH II+/– mice regardless of HPRT status (data not
shown). This result suggests that expression of IMPDH
type I in combination with a single allele of IMPDH type
II does not compensate during lymphocyte activation
either for the loss of the second allele of the type II gene
or for the loss of HPRT activity.
T- and B-cell development and distribution. To examine
the development of the T and B cells in mutant mice,
flow cytometric analysis of thymocytes, bone marrow
cells, and splenocytes was performed. There were no
significant differences in the size of the thymus or
spleen or in the number of cells from these organs.
There were no significant differences among the four
mice genotypes in T-cell development in the thymus, in
B-cell development in the bone marrow, or in T- and B-
cell distribution in the spleen (data not shown).
Effect of IMPDH and HPRT mutations on lymphocyte
activation and drug sensitivity. Splenocytes from the four
groups of mice were cultured in the presence of a vari-
ety of T- or B-cell activators, and cell proliferation was
measured at 24, 48, and 72 hours after stimulation by
measuring 3H-thymidine incorporation into DNA. As
shown in Figure 5, there were no significant differ-
ences in response to Con A stimulation of T cells (Fig-
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Figure 1
Schema illustrating the pathways of de novo and salvage purine
nucleotide biosynthesis. Solid lines represent the de novo purine
biosynthetic pathway, and dashed lines indicate salvage pathways.
APRT, adenine phosphoribosyltransferase; AMP-DA, AMP-deaminase.
Figure 2
Targeted disruption of the IMPDH type II gene. (a) Restriction
map of the wild-type IMPDH type II locus, the knock-out con-
struct, and the expected recombinant allele. Exons are indicated
by boxes. The two BglII fragments expected from the wild-type (11
kb) and recombinant (6 kb) alleles are shown, and the probe used
for Southern hybridization is indicated. P indicates the PGK pro-
moter. (b) Southern blot showing 11-kb and 6-kb bands in four
heterozygous ES clones.
ure 5a) or LPS stimulation of B cells (Figure 5b). Pro-
liferation in response to PMA plus ionomycin, how-
ever, was moderately reduced at 72 hours in lympho-
cytes from IMPDH+/– animals (Figure 5c). Very
significant inhibition was seen with the use of anti-
CD3 and -CD28 antibodies as costimulators, with a
50–75% reduction in proliferation in IMPDH II+/–,
HPRT–/o mice as compared with wild-type (Figure 5d).
These results suggest that although guanine
nucleotide synthesis is important for cell proliferation
in general, T cells are more sensitive than B cells to
these effects. Proliferation in response to T-cell recep-
tor activation in conjunction with CD28 costimula-
tion appears to be most sensitive to the effects of gua-
nine nucleotide depletion.
To test whether T cells from IMPDH+/–, HPRT–/o mice
would be more sensitive to IMPDH inhibitor, T cells
were stimulated by either anti-CD3 plus anti-CD28
antibodies (Figure 6a) or Con A (Figure 6b) in the
absence or presence of various doses of MPA, a specific
IMPDH inhibitor. Proliferation of splenocytes from
mutant mice is significantly more sensitive to the
inhibitor as compared with wild-type cells under both
stimulation conditions.
To determine whether mutant mice produce normal
levels of immunoglobulins, wild-type and mutant mice
were injected with NP20-chicken γ globulin to elicit a T
cell–dependent B-cell response. Serum IgM and IgG
level was measured before, 7 days after, and 19 days after
immunization. No significant differences were found
between wild-type and mutant mice (data not shown).
Cytotoxic T-cell function was assayed 5 days after an
MLR as described in Methods. The cytolytic activity of
the lymphocytes was determined by a standard 51Cr-
release assay. There was a consistent, statistically signif-
icant, 20–30% decrease in killing activity in cells from
IMPDH II+/–, HPRT–/o mice compared with cells from
wild-type mice (Figure 7). To further determine whether
mutant mice have a reduction in the ability to expand
CD8-positive T cells upon viral infection, wild-type and
mutant mice were injected with lymphocytic chori-
omeningitis virus and total CD8 T cells were quantitat-
ed before and 9 days after infection using flow cytome-
try. There was no significant difference in CD8-cell
expansion between these groups (11.43 to 31.68% [±
4.9%], wild-type; 10.61 to 28.49% [± 7.5%], mutant).
Effect of IMPDH and HPRT mutations on purine
nucleotide pools. Intracellular nucleoside triphosphate
levels of ATP and GTP were measured in both resting
and mitogen-stimulated splenocytes, and values were
compared between the wild-type and IMPDH II+/–,
HPRT–/o mice (Figure 8). GTP levels were approximate-
ly 30% lower in lymphocytes from mutant mice as
compared with the wild-type mice after anti-CD3 plus
anti-CD28 antibody stimulation (P < 0.003). There was
a slight decrease in GTP levels in Con A–stimulated
cells that did not achieve statistical significance. There
was no significant difference in ATP levels between the
wild-type and mutant mice.
Discussion
IMPDH enzymatic activity is greatly increased in
cells that are proliferating or have undergone malig-
nant transformation (5, 9, 10) and is reduced in cells
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Figure 3
PCR genotyping of mouse blastocysts. Blastocysts were isolated from
IMPDH II+/– breeding females at 3.5 dpc. PCR was performed using
two sets of oligonucleotide primers. Lane 1 contains molecular
weight markers of lambda HindIII plus PhiX174 Hae III. Lanes 2–4
are examples of heterozygotes, since they have both wild-type (WT)
and knock-out (KO) bands; lanes 5 and 6 are examples of wild-type;
and lanes 7 and 8 are examples of homozygotes. Lane 9 contains tail
DNA from an IMPDH II heterozygous animal, and lane 10 represents
a PCR reaction in the absence of DNA.
Figure 4
Northern blot analysis of IMPDH type I, type II, and HPRT mRNAs. (a)
15 µg of total RNA from resting (lanes 1, 3, 5, and 7) or Con A–acti-
vated (lanes 2, 4, 6, and 8) splenocytes from mice of four different geno-
types was probed with IMPDH type I, type II, or HPRT cDNAs as indi-
cated. (b) Northern hybridizations were performed on 20 µg of total
RNA from various tissues of wild-type and IMPDH II+/–, HPRT–/o mice.
induced to differentiate (20, 24). These observations
constitute indirect evidence that the de novo path-
way of guanine nucleotide biosynthesis is important
in the overall regulation of cell growth and differen-
tiation. Inhibitors of IMPDH activity are in clinical
use as immunosuppressive drugs in the setting of
organ transplantation and graft-versus-host disease
(18, 19, 25). Despite this apparently selective clinical
effect on T-lymphocyte responses in vivo, IMPDH
inhibitors impair the activation of both T and B lym-
phocytes in vitro (26, 27) and, at somewhat higher
concentration, also inhibit the proliferation of a
number of cell lines (27, 28). Given the roughly
equivalent inhibitory effects of IMPDH inhibitors
on the activities of both type I and type II IMPDH
isoenzymes, it has not been feasible to determine the
relative roles of these isoenzymes in T-lymphocyte
proliferative and functional responses. In order to
determine the effects of loss of IMPDH type II
expression on both cell growth and lymphocyte
responsiveness in vivo, we have attempted to create
a mouse model with selective deficiency of the
IMPDH type II gene.
We have demonstrated that homozygous loss of
IMPDH type II gene expression results in very early
embryonic lethality. Of the blastocysts analyzed, only 6%
demonstrated targeting of both IMPDH II alleles, strong-
ly suggesting that loss of the IMPDH type II enzyme
does not permit the further development of fertilized
ova. Previous studies have suggested a critical role for
purines, especially for guanosine and hypoxanthine, in
the maintenance of oocytes in meiotic arrest (29).
Inhibitors of IMPDH such as MPA induced premature
meiotic maturation and resulted in a significant loss of
implantation capacity and viability after implantation
(30). Our results also indicate that a small percentage of
homozygous-deficient embryos may have implanted but
underwent resorption shortly after, supporting an
absolute requirement for IMPDH type II expression dur-
ing this developmental stage and indicating that neither
IMPDH type I activity nor HPRT activity with supple-
mental guanosine added to the maternal drinking water
could substitute for IMPDH type II. Since a dramatic
increase in embryonic growth rate is known to occur
after implantation around 4.5 dpc (31), and since
increases in the synthesis of guanine nucleotides are gen-
erally required to sustain increased cell proliferation, it
seems highly likely that defective synthesis of guanine
nucleotides is responsible for the embryonic lethality.
The requirement for guanine nucleotide biosynthesis
for cell proliferation and the central role of IMPDH
type II in this process are underscored by the upregula-
tion of IMPDH II gene expression that occurs in the
face of guanine nucleotide depletion (32). Our study
indicates that, in the mouse model, neither IMPDH
type I or HPRT expression can be increased in a similar
compensatory fashion in the absence of IMPDH type
II activity. We conclude from these data that the evolu-
tionary conservation of two IMPDH genes encoding
nearly identical proteins results from their differential
regulation at the transcriptional level. The IMPDH type
I gene is expressed in humans in a complex manner,
with three different transcripts arising from three pro-
moter regions 5′ to the gene (4), suggesting a require-
ment for tissue-specific and/or developmentally spe-
cific expression of this isoenzyme. Whether or not
IMPDH type I is required for organ-specific develop-
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Figure 5
Effect of loss of IMPDH II and/or HPRT activities on mouse splenocyte proliferation. Mouse splenocytes were stimulated with Con A (a), LPS (b),
PMA plus ionomycin (c), or anti-CD3 plus anti-CD28 (d) for 24, 48, and 72 hours. Proliferation of T or B cells from wild-type (closed circles),
HPRT–/o (open circles), IMPDH II+/– (closed triangles), and IMPDH II+/–, HPRT–/o (open triangles) mice was measured by 3H-thymidine incorpora-
tion. n = 3 for HPRT–/o or IMPDH II+/– mice; n = 5 for IMPDH II+/–, HPRT–/o or wild-type mice. Values are means ± SD. AP < 0.04; BP < 0.003.
Figure 6
Effect of loss of IMPDH II and HPRT activity on drug sensitivity. Wild-
type (closed circles) or mutant (open circles) splenocytes were stim-
ulated with either antibodies (a) or Con A (b) in the absence or pres-
ence of increasing concentrations of MPA. Data represent one of
three highly similar experiments performed in triplicate (± SD) and
are plotted as the percentage of proliferation in the absence of drug.
ment will have to be determined in studies on mice
deficient in type I gene expression. IMPDH type II, on
the other hand, is less restricted in its expression but is
strongly upregulated at the transcriptional level by a
promoter region that responds directly to growth stim-
uli (3, 33). The latter finding supports a more specific
role in supporting cell proliferation.
A major reason for undertaking these studies was to
determine whether loss of IMPDH type II protein
would result in immunodeficiency analogous to that
produced by inhibitors of the enzymes and, if so, by
what mechanism. We have clearly shown that marked
increases in the expression of both IMPDH isoenzymes
in murine splenocytes result from T-cell mitogen stim-
ulation. Loss of a single allele of IMPDH type II does
not impair the mitogenic response, nor does it have any
other demonstrable effects on the mouse phenotype.
Given the prevailing hypothesis that deficiency of gua-
nine nucleotides is causally related to the immunode-
ficiency resulting from IMPDH inhibition, we mated
IMPDH heterozygous mice to HPRT-deficient mice to
ask whether elimination of the salvage pathway would
enhance the effects of loss of one IMPDH II allele.
Although HPRT is frequently referred to as a “house-
keeping” enzyme, it is clear from the present study that
its expression also increases markedly with the activa-
tion of murine splenocytes.
Lymphocyte subsets from IMPDH+/–, HPRT–/o mice
were not significantly different from those in wild-type
mice in the thymus, bone marrow, or spleen. However,
the splenocytes from these animals demonstrated a
very significant decrease in the proliferative response to
anti-CD3 and anti-CD28 stimulation as compared
with values from control mice and mice containing
either mutation alone. In contrast, there was no signif-
icant difference in splenocyte responsiveness to LPS or
Con A, and the response at 72 hours to PMA and iono-
mycin was only mildly reduced. Nucleotide pool data
demonstrated a 25–30% reduction (P < 0.003), upon
antibody stimulation, in the ability of IMPDH+/–,
HPRT–/o splenocytes to increase GTP levels, compared
with the wild type, whereas the GTP levels in Con
A–stimulated cells were reduced by only 10–15%. These
data demonstrate that guanine nucleotide biosynthe-
sis during lymphocyte activation via CD3 and CD28
costimulation is dependent on increased synthesis
through both the de novo and salvage pathways. In
addition, a relatively small reduction in the ability of
lymphocytes to increase guanine nucleotide levels fol-
lowing activation via the T-cell receptor and CD28 sig-
nificantly inhibits T-cell responsiveness. Explanations
for these results include the possibilities (a) that lym-
phocyte response to mitogens such as Con A and LPS
requires a lesser degree of GTP increase, and (b) that
some component of the CD3/CD28 activation path-
way is specifically dependent on a threshold level of
GTP for signal transduction, as many studies have
already demonstrated an important role for a number
of G proteins and T-cell activation (34–36).
Finally, we have shown that the cytolytic T-cell func-
tion is reduced in IMPDH+/–, HPRT–/o mice, although
numerical expansion of CD8+ T cells is similar in
mutant and wild-type animals after LCMV infection.
There are several pieces of evidence indicating that GTP
is crucial in the signaling events in cytotoxic T lym-
phocytes that culminate in the exocytosis of cytoplas-
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Figure 7
Effect of mutations on the cytolytic activity of cytotoxic T lympho-
cytes. The function of cytotoxic T lymphocytes from wild-type (open
squares) and IMPDH II+/–, HPRT–/o (closed squares) mice was ana-
lyzed in a 51Cr-release assay. A representative experiment performed
in triplicate is shown. P values were calculated from four experiments
performed in triplicate: P < 0.05 at E:T = 1:1; P < 0.015 at E:T = 3:1;
P < 0.012 at E:T = 9:1, 27:1, and 50:1.
Figure 8
Alterations in ATP (closed bars) and GTP (hatched bars) levels in
splenocytes of IMPDH II+/–, HPRT–/o mice as a function of lympho-
cyte activation. Values were determined after 48 hours of stimulation
with Con A or antibodies, are plotted as the percentage of values
obtained from wild-type splenocytes under similar conditions, and
represent the mean ± SD from duplicate determinations on five ani-
mals. AP < 0.0027. Nucleotide levels (nmol/107 cells) for wild-type
resting splenocytes were 2.105 (ATP) and 0.27 (GTP). Levels of GTP
were increased by 3.4-fold ± 0.8-fold after Con A stimulation, and
by 7.7-fold ± 2.6-fold following Ab stimulation.
mic granules containing perforin and the serine pro-
teases granzyme A and B, causing apoptosis of target
cells (37–39). The question of which signaling path-
ways are affected by impaired synthesis of guanine
nucleotides will best be worked out in a genetic model
of IMPDH deficiency.
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